8-K filings / November 13, 2026
Apnimed, Inc.: Financial statements that should no longer be relied upon
Apnimed, Inc. filed a current report (Form 8-K) with the SEC on November 13, 2026. It reports financial statements that should no longer be relied upon.
Item 4.02
Financial statements no longer to be relied upon
-
Conclusion
Earlier financial statements should no longer be relied upon
From the filing
Source
“On November 13, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Apnimed, Inc. (the “Company”), based on the recommendation of the Company’s management, concluded that the Company’s previously issued financial statements, as described below, should no longer be relied upon due to an error identified in the classification of the gain on the disposition of the Company’s equity method investment in Shionogi-Apnimed Sleep Science, LLC (“SASS”) for the three and six months ended June 30, 2026 as a gain in continuing operations rather than discontinued operations.”
Read by code from this sentence of the filing. -
Concluded on
November 13, 2026
From the filing
Source
“On November 13, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Apnimed, Inc. (the “Company”), based on the recommendation of the Company’s management, concluded that the Company’s previously issued financial statements, as described below, should no longer be relied upon due to an error identified in the classification of the gain on the disposition of the Company’s equity method investment in Shionogi-Apnimed Sleep Science, LLC (“SASS”) for the three and six months ended June 30, 2026 as a gain in continuing operations rather than discontinued operations.”
Read by code from this sentence of the filing. -
Concluded by
The audit committee
From the filing
Source
“On November 13, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Apnimed, Inc. (the “Company”), based on the recommendation of the Company’s management, concluded that the Company’s previously issued financial statements, as described below, should no longer be relied upon due to an error identified in the classification of the gain on the disposition of the Company’s equity method investment in Shionogi-Apnimed Sleep Science, LLC (“SASS”) for the three and six months ended June 30, 2026 as a gain in continuing operations rather than discontinued operations.”
Read by code from this sentence of the filing. -
Period
three and six months ended June 30, 2026
From the filing
Source
“On November 13, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Apnimed, Inc. (the “Company”), based on the recommendation of the Company’s management, concluded that the Company’s previously issued financial statements, as described below, should no longer be relied upon due to an error identified in the classification of the gain on the disposition of the Company’s equity method investment in Shionogi-Apnimed Sleep Science, LLC (“SASS”) for the three and six months ended June 30, 2026 as a gain in continuing operations rather than discontinued operations.”
Read by code from this sentence of the filing. -
Reason given
an error identified in the classification of the gain on the disposition of the Company’s equity method investment in Shionogi-Apnimed Sleep Science, LLC (“SASS”) for the three and six months ended June 30, 2026 as a gain in continuing operations rather than discontinued operations
From the filing
Source
“an error identified in the classification of the gain on the disposition of the Company’s equity method investment in Shionogi-Apnimed Sleep Science, LLC (“SASS”) for the three and six months ended June 30, 2026 as a gain in continuing operations rather than discontinued operations”
Found by an AI model; the quote is checked word for word against the filing.
Not investment advice.Read the filing on SEC.gov
Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.